Literature DB >> 18502259

The administration of folic acid reduces intravascular oxidative stress in diabetic rabbits.

Nilima Shukla1, Gianni D Angelini, Jamie Y Jeremy.   

Abstract

There is evidence that plasma homocysteine augments angiopathy in patients with diabetes mellitus. Although lowering homocysteine with folic acid improves endothelial function, the precise mechanisms underlying this effect are unknown. To study this area further, the effect of administration of folic acid to diabetic rabbits on intraaortic oxidative stress was studied by assessing the formation of superoxide (O(2)(-)), 8-isoprostane F(2alpha) (8-IPF(2alpha)), and prostacyclin (as 6-keto-PGF(1alpha)) as well as acetylcholine-stimulated relaxation and gp47(phox) content. Nonketotic diabetes mellitus was induced in New Zealand rabbits with alloxan, and low- and high-dose folic acid was administered daily for 1 month. Rabbits were killed, aortae were excised, and rings were prepared. Rings were mounted in an organ bath, and relaxation was elicited with acetylcholine. The O(2)(-) release was measured spectrophotometrically; the gp47(phox) expression, by Western blotting; and the 8-IPF(2alpha) and 6-keto-PGF(1alpha) formation, by enzyme-linked immunosorbent assay. Blood was collected for measurement of homocysteine, red blood cell folate, and glucose. In aortae from the diabetic rabbits, acetylcholine-induced relaxation was significantly impaired compared with that in untreated controls. The O(2)(-) release, p47(phox) expression, and 8-IPF(2alpha) formation were all enhanced and 6-keto-PGF(1alpha) formation was reduced compared with controls. All these effects were reversed by both low- and high-dose folic acid. Plasma total homocysteine was reduced by high-dose, but not low-dose, folic acid. Red blood cell folate was elevated in both groups. The improvement of endothelial function in patients receiving folic acid may be due to inhibition of nicotinamide adenine nucleotide phosphate oxidase (NADPH) oxidase expression and therefore conservation of nitric oxide and prostacyclin bioavailability, 2 vasculoprotective factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502259     DOI: 10.1016/j.metabol.2008.01.017

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  Folic acid administration reduces neointimal thickening, augments neo-vasa vasorum formation and reduces oxidative stress in saphenous vein grafts from pigs used as a model of diabetes.

Authors:  J Bloor; N Shukla; F C T Smith; G D Angelini; J Y Jeremy
Journal:  Diabetologia       Date:  2010-02-25       Impact factor: 10.122

2.  Attenuation of beta2-adrenergic receptors and homocysteine metabolic enzymes cause diabetic cardiomyopathy.

Authors:  Paras Kumar Mishra; Srikanth Givvimani; Naira Metreveli; Suresh C Tyagi
Journal:  Biochem Biophys Res Commun       Date:  2010-09-15       Impact factor: 3.575

3.  Folic acid may be a potential addition to diabetic foot ulcer treatment - a hypothesis.

Authors:  Mansooreh Bagheri; Behnam Moein Jahromi; Ali Zamani
Journal:  Int Wound J       Date:  2011-08-19       Impact factor: 3.315

4.  Effect of hydrogen sulphide-donating sildenafil (ACS6) on erectile function and oxidative stress in rabbit isolated corpus cavernosum and in hypertensive rats.

Authors:  Nilima Shukla; Giuseppe Rossoni; Matthew Hotston; Anna Sparatore; Piero Del Soldato; Valerio Tazzari; Raj Persad; Gianni D Angelini; Jamie Y Jeremy
Journal:  BJU Int       Date:  2009-03-26       Impact factor: 5.588

5.  Effects of Folate Supplementation on Carotid Intima-Media Thickness, Biomarkers of Inflammation, and Oxidative Stress in Carbamazepine-Treated Epileptic Children.

Authors:  Hamid Reza Talari; Mansour Bahrami; Ahmad Talebian Ardestani; Fereshteh Bahmani; Peyman Famili; Zatollah Asemi
Journal:  Int J Prev Med       Date:  2019-01-15

6.  Palm tocotrienol-rich fraction improves vascular proatherosclerotic changes in hyperhomocysteinemic rats.

Authors:  Ku-Zaifah Norsidah; Ahmad Yusof Asmadi; Ayob Azizi; Othman Faizah; Yusof Kamisah
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-20       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.